Response to "zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: Sex as differentiating factor"

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 957-958

  Polasek, Thomas M ^a   Miners, John O ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; TESTOSTERONE; ZOLPIDEM;

AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE; GENDER; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77956192260     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0855-9     Document Type: Letter

References (21)

1. MM Cotreau LL von Moltke DJ Greenblatt 2005 The influence of age and sex on the clearance of cytochrome P450 3A substrates Clin Pharmacokinet 44 33 60 10.2165/00003088-200544010-00002 1:CAS:528:DC%2BD2MXhsVeisLY%3D 15634031
2. DJ Greenblatt LL von Moltke 2008 Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs J Clin Pharmacol 48 1350 1355 10.1177/0091270008323754 1:CAS:528:DC%2BD1cXhtlyrs7bE 18757784
3. T Sakuma Y Kawasaki K Jarukamjorn N Nemoto 2009 Sex differences of drug-metabolizing enzyme: female predominant expression of human and mouse cytochrome P450 3A isoforms J Health Sci 55 328 337 10.1248/jhs.55.325
4. OP Soldin DR Mattison 2009 Sex differences in pharmacokinetics and pharmacodynamics Clin Pharmacokinet 48 143 157 10.2165/00003088-200948030-00001 1:CAS:528:DC%2BD1MXmtlant7g%3D 19385708
5. J Nicolas P Espie M Molimard 2009 Gender and interindividual variability in pharmacokinetics Drug Metab Rev 41 408 421 10.1080/10837450902891485 1:CAS:528:DC%2BD1MXosV2mtL4%3D 19601720
6. M Gandhi F Aweeka RM Greenblatt TF Blaschke 2004 Sex differences in pharmacokinetics and pharmacodynamics Annu Rev Pharmacol Toxicol 44 499 523 10.1146/annurev.pharmtox.44.101802.121453 1:CAS:528:DC%2BD2cXhvVCktb8%3D 14744256
7. JB Schwartz 2003 The influence of sex on pharmacokinetics Clin Pharmacokinet 42 107 121 10.2165/00003088-200342020-00001 1:CAS:528: DC%2BD3sXhsFyntbs%3D 12537512
8. DJ Greenblatt JS Harmatz LL von Moltke CE Wright AL Durol LM Harrel-Joseph RI Shader 2000 Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences Drug Metab Dispos 293 435 443 1:CAS:528:DC%2BD3cXkvFWgsb0%3D
9. JO Olubodun HR Ochs LL von Moltke R Roubenoff LM Hesse JS Harmatz RI Shader DJ Greenblatt 2003 Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone Br J Clin Pharmacol 56 297 304 10.1046/j.0306-5251.2003.01852.x 1:CAS:528:DC%2BD3sXnvVSguro%3D 12919178
10. P Salvà J Costa 1995 Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications Clin Pharmacokinet 29 142 153 10.2165/00003088-199529030-00002 8521677
11. A Galetin SE Clarke JB Houston 2002 Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach Drug Metab Dispos 30 1512 1522 10.1124/dmd.30.12.1512 1:CAS:528:DC%2BD38XptVyisbY%3D 12433827
12. A Galetin SE Clarke JB Houston 2003 Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine Drug Metab Dispos 31 1108 1116 10.1124/dmd.31.9. 1108 1:CAS:528:DC%2BD3sXmslKlurY%3D 12920166
13. KE Kenworthy JC Bloomer SE Clarke JB Houston 1999 CYP3A4 drug interactions: correlation of 10 in vitro probe substrates Br J Clin Pharmacol 48 716 727 10.1046/j.1365-2125.1999.00073.x 1:CAS:528:DyaK1MXnvFSrtr8%3D 10594474
14. KE Kenworthy SE Clarke J Andrews JB Houston 2001 Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism Drug Metab Dispos 29 1644 1651 1:CAS:528:DC%2BD3MXovFKrtL4%3D 11717184
15. RW Wang DJ Newton N Liu WM Atkins AY Lu 2000 Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent Drug Metab Dispos 28 360 366 1:CAS:528:DC%2BD3cXhsVOit78%3D 10681383
16. Cubala WJ, Wiglusz M, Burkiewicz A, Galuszko-Wegielnil M (2010) Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as differentiating factor. Eur J Clin Pharmacol; in press
17. TM Polasek JS Sadagopal DJ Elliot JO Miners 2010 In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A Eur J Clin Pharmacol 66 275 283 10.1007/s00228-009-0760-2 1:CAS:528:DC%2BC3cXitVOgsbw%3D 20012430
18. WJ Cubala J Landowski HM Wichowicz 2008 Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects Br J Clin Pharmacol 65 444 445 10.1111/j.1365-2125.2007.03028.x 17875189
19. RS Obach RL Walsky K Venkatakrishnan 2007 Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions Drug Metab Dispos 35 246 255 10.1124/dmd.106.012633 1:CAS:528:DC%2BD2sXhvVKrs7k%3D 17093004
20. K Rowland Yeo M Jamei J Yang GT Tucker A Rostami-Hodjegan 2010 Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam Eur J Pharm Sci 39 298 309 10.1016/j.ejps.2009.12.002 1:CAS:528:DC%2BC3cXjtVWksbs%3D 20025966
21. TM Polasek JO Miners 2007 In vitro approaches to investigate mechanism-based inactivation of CYP enzymes Expert Opin Drug Metab Toxicol 3 321 329 10.1517/17425255.3.3.321 1:CAS:528:DC%2BD2sXlvFaktrY%3D 17539741